Oral Therapy Drug for Multiple Sclerosis Gets Approval

Biogen Idec Biotech India, has received approval for the first oral therapy drug for multiple sclerosis, Tecfidera by the DCGI.

The national drug controller, Drug Controller General of India (DCGI), has approved a new oral therapy drug for multiple sclerosis, developed by Biogen Idec Biotech India.

The company has received approval for the first oral therapy drug for multiple sclerosis, Tecfidera by the DCGI.

Multiple sclerosis - Symptoms - Causes - Diagnosis - Treatment
Multiple sclerosis can be a severely disabling autoimmune disease that affects the myelin or insulating layer of the nerve fibers and typically has remissions and relapses

Biogen Idec India Acting Managing Director Pooja Vatsyayan said, "We believe Tecfidera provides a new option for patients in India, particularly as it provides the convenience of oral dosing."

The clinical trials conducted for the approval of the drug involved two-phase III studies more than 2600 patients all around the world. Patients from India also were part of clinical research, Biogen Idec India said.

Tecfidera is the first oral drug for the treatment of relapsing-remitting multiple sclerosis (RRMS) in India, it added.

Multiple Sclerosis – Treatment to Reduce Symptoms and Modify course of Disease
Multiple sclerosis is treated with drugs that modify the course of the disease, suppress immunity and relieve symptoms.

Multiple sclerosis is a disease, which affects brain and spinal cord and is the most common cause of non-traumatic neurological disability afflicting young adults, Biogen Idec India said.

Source-Medindia

Vitamin B12 - An Essential Vitamin
If you feel that the persistent or regular incidences of depression have got nothing to do with what you eat, think again. The reason behind low spirits can be due to insufficient levels vitamin B12.